Literature DB >> 35665374

Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm.

Daniel Y Lee1,2.   

Abstract

How cancers are characterized and treated has evolved over the past few decades. Major advances in genomics tools and techniques have revealed interlinked regulatory pathways of cancers with unprecedented detail. Early discoveries led to success with rationally targeted small molecules and more recently with immunomodulatory agents, setting the stage for precision oncology. However, drug resistance to every agent has thus far proven intractable, sending us back to fill the gaps in our rudimentary knowledge of tumor biology. Epigenetics is emerging as a fundamental process in every hallmark of cancer. Large-scale interrogation of the cancer epigenome continues to reveal new mechanisms of astounding complexity. In this review, I present selected experimental and clinical examples that have shaped our understanding of cancer at the molecular level. Translation of our collective erudition into revolutionary diagnostic and treatment strategies will advance the precision oncology paradigm. © Innovative Healthcare Institute.

Entities:  

Keywords:  cancer; epigenomics; epitranscriptomics; genomics; immune checkpoint inhibitors; immuno-oncology; molecular therapy; noncoding RNA; targeted therapy

Year:  2020        PMID: 35665374      PMCID: PMC9165444          DOI: 10.36401/JIPO-20-18

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN: 2590-017X


  127 in total

Review 1.  Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

Authors:  Samuel J Klempner; David Fabrizio; Shalmali Bane; Marcia Reinhart; Tim Peoples; Siraj M Ali; Ethan S Sokol; Garrett Frampton; Alexa B Schrock; Rachel Anhorn; Prasanth Reddy
Journal:  Oncologist       Date:  2019-10-02

2.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 3.  Extrachromosomal oncogene amplification in tumour pathogenesis and evolution.

Authors:  Roel G W Verhaak; Vineet Bafna; Paul S Mischel
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

4.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

5.  Comprehensive mapping of long-range interactions reveals folding principles of the human genome.

Authors:  Erez Lieberman-Aiden; Nynke L van Berkum; Louise Williams; Maxim Imakaev; Tobias Ragoczy; Agnes Telling; Ido Amit; Bryan R Lajoie; Peter J Sabo; Michael O Dorschner; Richard Sandstrom; Bradley Bernstein; M A Bender; Mark Groudine; Andreas Gnirke; John Stamatoyannopoulos; Leonid A Mirny; Eric S Lander; Job Dekker
Journal:  Science       Date:  2009-10-09       Impact factor: 47.728

6.  Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Authors:  Guillermo Garcia-Manero; Gail Roboz; Katherine Walsh; Hagop Kantarjian; Ellen Ritchie; Patricia Kropf; Casey O'Connell; Raoul Tibes; Scott Lunin; Todd Rosenblat; Karen Yee; Wendy Stock; Elizabeth Griffiths; Joseph Mace; Nikolai Podoltsev; Jesus Berdeja; Elias Jabbour; Jean-Pierre J Issa; Yong Hao; Harold N Keer; Mohammad Azab; Michael R Savona
Journal:  Lancet Haematol       Date:  2019-05-03       Impact factor: 18.959

Review 7.  The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.

Authors:  Richard J Epstein
Journal:  Front Oncol       Date:  2013-12-12       Impact factor: 6.244

8.  Patterns of somatic structural variation in human cancer genomes.

Authors:  Yilong Li; Nicola D Roberts; Jeremiah A Wala; Ofer Shapira; Steven E Schumacher; Kiran Kumar; Ekta Khurana; Sebastian Waszak; Jan O Korbel; James E Haber; Marcin Imielinski; Joachim Weischenfeldt; Rameen Beroukhim; Peter J Campbell
Journal:  Nature       Date:  2020-02-05       Impact factor: 49.962

Review 9.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

10.  Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Authors:  H Yang; C Bueso-Ramos; C DiNardo; M R Estecio; M Davanlou; Q-R Geng; Z Fang; M Nguyen; S Pierce; Y Wei; S Parmar; J Cortes; H Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.